Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Genedrive commences HCV ID Kit sales to EMEA region, reveals first commercial Asia-Pacific sales

The AIM-listed firm said the products have been shipped to Genedrive’s distributor, Sysmex Corporation, and are now destined for use in various initial target countries
testing
Genedrive said the products have been shipped to its EMEA distributor, Sysmex Corporation and are now destined for use in various initial target countries

Genedrive PLC (LON:GDR) shares rose on Tuesday as the firm announced that it has commenced commercial sales and shipments of its Genedrive HCV ID Kit, a qualitative molecular assay for HCV and Genedrive platform into the EMEA (Europe, Middle East, and Africa) region, with an initial focus on Africa.

In addition, the AIM-listed firm revealed its first commercial sales and shipment of the HCV ID kit and platform are expected to commence in the Asia Pacific region in the coming weeks.

READ: Genedrive surges after receiving £1.1mln in funding to finance development of its TB testing kit

In early morning trading, Genedrive shares were 2.9% higher at 36p.

Genedrive said the products have been shipped to its EMEA distributor, Sysmex Corporation, a world leader in clinical laboratory systemisation and solutions, and are now destined for use in various initial target countries.

David Budd, CEO of Genedrive, said: "Since signing our distribution agreements with Sysmex, we have continued to build momentum in the market and we are pleased to see initial commercial sales.

"An ongoing process of registering the products in target countries will naturally lead to a growing opportunity, and we are confident that as the first to market decentralised qualitative molecular HCV test, Genedrive is uniquely positioned to meet this need."

He added: With the advent of new 'curative' direct acting antiviral treatments for Hepatitis C (HCV), genedrive and Sysmex believe that there is a major opportunity to support tackling the global burden of the disease if accurate, decentralised diagnostics can be used to identify those living with HCV and give them access to therapy. These first sales mark a further important step towards that goal."

The Genedrive HCV ID Kit, a qualitative molecular assay for HCV has received CE-IVD Certification from the European Union.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

syringe
June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use